Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer

Published:2018-07-26 Issue:9 Volume:7 Page:e1466017
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Matikas Alexios¹,Lövrot John¹^ORCID,Ramberg Anna²,Eriksson Margareta²,Lindsten Therese²^ORCID,Lekberg Tobias¹,Hedenfalk Ingrid³,Loman Niklas³,Bergh Jonas¹,Hatschek Thomas¹,Erlandsson Ann⁴⁵,Foukakis Theodoros¹

Affiliation:

1. Department of Oncology, Karolinska Institutet and University Hospital, Stockholm, Sweden

2. Department of Clinical Pathology and Cytology, Central Hospital Karlstad, Karlstad, Sweden

3. Department of Oncology/Pathology, Lund University, Lund, Sweden

4. Department of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

5. Department of Biology, Karlstad university, Karlstad, Sweden

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1466017

Reference29 articles.

1. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States

2. Early Breast Cancer Trialists’ Collaborative G. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018 Jan;19(1):27–39.

3. Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

4. Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer;Nature Communications;2024-05-07

2. Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy;International Journal of Molecular Sciences;2024-02-23

3. Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis;Frontiers in Oncology;2022-11-30

4. NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation;Cancers;2022-06-15

5. Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution;Cancers;2022-04-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3